Wild CP, Weiderpass E, Stewart BW, editors. (2020). World Most cancers Report: Most cancers Analysis for Most cancers Prevention. World Well being Group. ISBN-13: 978-92-832-0447-3; ISBN-13: 978-92-832-0448-0.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. World most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. Most cancers J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
Cheung-Ong Okay, Giaever G, Nislow C. DNA-damaging brokers in most cancers chemotherapy: serendipity and chemical biology. Chem Biol. 2013;20(5):648–59. https://doi.org/10.1016/j.chembiol.2013.04.007.
Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et al. Doxorubicin: the great, the unhealthy and the ugly impact. Curr Med Chem. 2009;16(25):3267–85. https://doi.org/10.2174/092986709788803312.
Schirrmacher V. From chemotherapy to organic remedy: a overview of novel ideas to cut back the negative effects of systemic most cancers therapy (Assessment). Int J Oncol. 2019;54(2):407–19. https://doi.org/10.3892/ijo.2018.4661.
Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Evaluation of nanoparticle supply to tumours. Nat Rev Mater. 2016;1(5):16014. https://doi.org/10.1038/natrevmats.2016.14.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanoparticles as an rising platform for most cancers remedy. Nat Nanotechnol. 2007;2(12):751–60. https://doi.org/10.1038/nnano.2007.387.
Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an rising therapy modality for most cancers. Nat Rev Drug Discov. 2008;7(9):771–82. https://doi.org/10.1038/nrd2614.
Xinchen Y, Jing T, Jiaoqiong G. Lipid-based nanoparticles by way of nose-to-brain supply: a mini overview. Entrance Cell Dev Biol. 2023;11:1214450. https://doi.org/10.3389/fcell.2023.1214450.
Sheoran S, Arora S, Samsonraj R, Govindaiah P, vuree S. Lipid-based nanoparticles for therapy of most cancers. Heliyon. 2022;8(5):e09403. https://doi.org/10.1016/j.heliyon.2022.e09403.
Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a overview of FDA-approved supplies and medical trials up to now. Pharm Res. 2016;33(10):2373–87. https://doi.org/10.1007/s11095-016-1958-5.
Allen TM, Cullis PR. Liposomal drug supply techniques: from idea to medical functions. Adv Drug Deliv Rev. 2013;65(1):36–48. https://doi.org/10.1016/j.addr.2012.09.037.
Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug supply. Entrance Pharmacol. 2015;6:286. https://doi.org/10.3389/fphar.2015.00286.
Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug supply techniques in most cancers remedy: what is offered and what’s but to come back. Pharmacol Rev. 2016;68(3):701–87. https://doi.org/10.1124/pr.115.012070.
Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Most cancers nanotechnology: the affect of passive and energetic concentrating on within the period of contemporary most cancers biology. Adv Drug Deliv Rev. 2014;66:2–25. https://doi.org/10.1016/j.addr.2013.11.009.
Nichols JW, Bae YH. EPR: proof and fallacy. J Managed Launch: Official J Managed Launch Soc. 2014;190:451–64. https://doi.org/10.1016/j.jconrel.2014.03.057.
Maeda H. Towards a full understanding of the EPR impact in major and metastatic tumors in addition to points associated to its heterogeneity. Adv Drug Deliv Rev. 2015. https://doi.org/10.1016/j.addr.2015.01.002.
Danhier F. To use the tumor microenvironment: for the reason that EPR impact fails within the clinic, what’s the way forward for nanomedicine? J Managed Launch: Official J Managed Launch Soc. 2016;244(Pt A):108–21. https://doi.org/10.1016/j.jconrel.2016.11.015.
Maeda H, Nakamura H, Fang J. The EPR impact for macromolecular drug supply to strong tumors: enchancment of tumor uptake, decreasing of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71–9. https://doi.org/10.1016/j.addr.2012.10.002.
Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Amankwa L, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N. Improvement of a weak-base docetaxel by-product that may be loaded into lipid nanoparticles. J Managed Launch: Official J Managed Launch Soc. 2010;144(3):332–40. https://doi.org/10.1016/j.jconrel.2010.02.029.
Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges in the direction of focused supply of most cancers therapeutics. Nat Commun. 2018;9(1):1410. https://doi.org/10.1038/s41467-018-03705-y.
Rivankar S. An summary of doxorubicin formulations in most cancers remedy. J Most cancers Res Ther. 2014;10(4):853–8. https://doi.org/10.4103/0973-1482.139267.
Xing M, Yan F, Yu S, Shen P. Efficacy and cardiotoxicity of liposomal Doxorubicin-based chemotherapy in superior breast most cancers: a meta-analysis of ten randomized managed trials. PLoS ONE. 2015;10(7):e0133569. https://doi.org/10.1371/journal.pone.0133569.
Zhang J, Jiang H, Zhang J, Bao G, Zhang G, Wang H, et al. Effectiveness and security of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast most cancers: a real-world research. BMC Most cancers. 2021;21(1):1301. https://doi.org/10.1186/s12885-021-09050-6.
Mayer LD, Tai LCL, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal techniques containing doxorubicin entrapped in response to pH gradients. Biochim Et Biophys Acta (BBA) – Biomembr. 1990;1025(2):143–51. https://doi.org/10.1016/0005-2736(90)90091-2.
Abu Lila AS, Ishida T. Liposomal supply techniques: design optimization and present functions. Biol Pharm Bull. 2017;40(1):1–10. https://doi.org/10.1248/bpb.b16-00624.
Liu H, Zhao J, Xue Y, Zhang J, Bai H, Pan S, et al. X-ray-induced drug launch for most cancers remedy. Angew Chem Int Ed Engl. 2023;62(39):e202306100. https://doi.org/10.1002/anie.202306100.
Li L, Yang W-W, Xu D-G. Stimuli-responsive nanoscale drug supply techniques for most cancers remedy. J Drug Goal. 2019;27(4):423–33. https://doi.org/10.1080/1061186X.2018.1519029.
Jalani G, Tam V, Vetrone F, Cerruti M. Seeing, concentrating on and delivering with upconverting nanoparticles. J Am Chem Soc. 2018;140(35):10923–31. https://doi.org/10.1021/jacs.8b03977.
Moradi Kashkooli F, Jakhmola A, Hornsby TK, Tavakkoli JJ, Kolios MC. Ultrasound-mediated nano drug supply for treating most cancers: elementary physics to future instructions. J Managed Launch: Official J Managed Launch Soc. 2023;355:552–78. https://doi.org/10.1016/j.jconrel.2023.02.009.
Chen H, Zhao Y. Purposes of light-responsive techniques for most cancers theranostics. ACS Appl Mater Interfaces. 2018;10(25):21021–34. https://doi.org/10.1021/acsami.8b01114.
Wang X, Xuan Z, Zhu X, Solar H, Li J, Xie Z. Close to-infrared photoresponsive drug supply nanosystems for most cancers photo-chemotherapy. J Nanobiotechnol. 2020;18(1):108. https://doi.org/10.1186/s12951-020-00668-5.
Gyanani V, Haley JC, Goswami R. Challenges of present anticancer therapy approaches with deal with liposomal drug supply techniques. Prescribed drugs. 2021;14(9):835. https://doi.org/10.3390/ph14090835.
Dou Y, Hynynen Okay, Allen C. To warmth or to not warmth: challenges with medical translation of thermosensitive liposomes. J Management Launch. 2017;249:63–73. https://doi.org/10.1016/j.jconrel.2017.01.025.
Could JP, Li S-D. Hyperthermia-induced drug concentrating on. Skilled Opin Drug Deliv. 2013;10(4):511–27. https://doi.org/10.1517/17425247.2013.758631.
Ribeiro TP, Moreira JA, Monteiro FJ, Laranjeira MS. Nanomaterials in most cancers: reviewing the mix of hyperthermia and triggered chemotherapy. J Managed Launch. 2022;347:89–103. https://doi.org/10.1016/j.jconrel.2022.04.045.
(2024). Imunon, Part A, Randomized III, Blind D. Dummy-Managed Examine of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Utilizing Standardized Radiofrequency Ablation (RFA) Remedy Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm (Medical Trial Registration No. NCT02112656). clinicaltrials.gov. https://clinicaltrials.gov/research/NCT02112656
College of Oxford. (2023). PanDox: Feasibility of Enhanced Chemotherapy Supply to Non-resectable Main Pancreatic Tumours Utilizing Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Targeted Ultrasound (Medical Trial Registration No. NCT04852367). clinicaltrials.gov. https://clinicaltrials.gov/research/NCT04852367
(2024). Imunon, Part A, Randomized III, Double-Blinded. Dummy-Managed Examine of the Efficacy and Security of ThermoDox® (Thermally Delicate Liposomal Doxorubicin) in Mixture With Radiofrequency Ablation (RFA) In comparison with RFA-Alone within the Remedy of Non-Resectable Hepatocellular Carcinoma (Medical Trial Registration No. NCT00617981). clinicaltrials.gov. https://clinicaltrials.gov/research/NCT00617981
Regenold M, Bannigan P, Evans JC, Waspe A, Temple MJ, Allen C. Turning down the warmth: the case for delicate hyperthermia and thermosensitive liposomes. Nanomedicine: Nanatechnol Biology Med. 2022;40:102484. https://doi.org/10.1016/j.nano.2021.102484.
Amini SM, Rezayat SM, Dinarvand R, Kharrazi S, Jaafari MR. Gold cluster encapsulated liposomes: theranostic agent with stimulus triggered launch functionality. Med Oncol. 2023;40(5):126. https://doi.org/10.1007/s12032-023-01991-1.
Borys N, Dewhirst MW. Drug growth of lyso-thermosensitive liposomal doxorubicin: combining hyperthermia and thermosensitive drug supply. Adv Drug Deliv Rev. 2021;178:113985. https://doi.org/10.1016/j.addr.2021.113985.
Zhou C, Xie X, Yang H, Zhang S, Li Y, Kuang C, et al. Novel class of ultrasound-triggerable drug supply techniques for the improved therapy of tumors. Mol Pharm. 2019;16(7):2956–65. https://doi.org/10.1021/acs.molpharmaceut.9b00194.
Choi V, Rajora MA, Zheng G. Activating medicine with sound: mechanisms behind sonodynamic remedy and the position of nanomedicine. Bioconjug Chem. 2020;31(4):967–89. https://doi.org/10.1021/acs.bioconjchem.0c00029.
Wang J, Li Z, Pan M, Fiaz M, Hao Y, Yan Y, et al. Ultrasound-mediated blood-brain barrier opening: an efficient drug supply system for theranostics of mind ailments. Adv Drug Deliv Rev. 2022;190:114539. https://doi.org/10.1016/j.addr.2022.114539.
Lyon PC, Grey MD, Mannaris C, Folkes LK, Stratford M, Campo L, et al. Security and feasibility of ultrasound-triggered focused drug supply of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, part 1 trial. Lancet Oncol. 2018;19(8):1027–39. https://doi.org/10.1016/S1470-2045(18)30332-2.
Li H, Shi S, Wu M, Shen W, Ren J, Mei Z, Ran H, Wang Z, Tian Y, Gao J, Zhao H. iRGD Peptide-Mediated liposomal nanoparticles with photoacoustic/ultrasound Twin-Modality imaging for precision theranostics towards hepatocellular carcinoma. Int J Nanomed. 2021;166455–75. https://doi.org/10.2147/IJN.S325891.</p>
Lin C-Y, Javadi M, Belnap DM, Barrow JR, Pitt WG. Ultrasound delicate eLiposomes containing doxorubicin for drug concentrating on remedy. Nanomedicine: Nanatechnol Biology Med. 2014;10(1):67–76. https://doi.org/10.1016/j.nano.2013.06.011.
Qin H, Teng R, Liu Y, Li J, Yu M. Drug launch from gelsolin-targeted phase-transition nanoparticles triggered by low-intensity centered ultrasound. Int J Nanomed. 2022;17:61–71. https://doi.org/10.2147/IJN.S341421.
Purohit MP, Roy KS, Xiang Y, Yu BJ, Azadian MM, Muwanga G, Hart AR, Taoube AK, Lopez DG, Airan RD. (2023). Acoustomechanically activatable liposomes for ultrasonic drug uncaging. bioRxiv: The Preprint Server for Biology, 2023.10.23.563690. https://doi.org/10.1101/2023.10.23.563690
Kim Y-S, Ko MJ, Moon H, Sim W, Cho AS, Gil G, et al. Ultrasound-responsive liposomes for focused drug supply mixed with centered ultrasound. Pharmaceutics. 2022;14(7):1314. https://doi.org/10.3390/pharmaceutics14071314.
Zhu X, Guo J, He C, Geng H, Yu G, Li J, Zheng H, Ji X, Yan F. Ultrasound triggered image-guided drug supply to inhibit vascular reconstruction by way of paclitaxel-loaded microbubbles. Sci Rep. 2016;6(1):21683. https://doi.org/10.1038/srep21683.
Lentacker I, Geers B, Demeester J, De Smedt SC, Sanders NN. Design and analysis of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin supply: cytotoxicity and mechanisms concerned. Mol Ther. 2010;18(1):101–8. https://doi.org/10.1038/mt.2009.160.
de Matos MBC, Deckers R, van Elburg B, Lajoinie G, de Miranda BS, Versluis M, et al. Ultrasound-sensitive liposomes for triggered macromolecular drug supply: formulation and in vitro characterization. Entrance Pharmacol. 2019;10:1463. https://doi.org/10.3389/fphar.2019.01463.
Awad NS, Paul V, AlSawaftah NM, Husseini GA. Impact of phospholipid head group on ultrasound-triggered drug launch and mobile uptake of immunoliposomes. Sci Rep. 2023;13(1):16644. https://doi.org/10.1038/s41598-023-43813-4.
Foglietta F, Macrì M, Panzanelli P, Francovich A, Durando G, Garello F, et al. Ultrasound boosts doxorubicin efficacy towards delicate and resistant ovarian most cancers cells. Eur J Pharm Biopharm. 2023;183:119–31. https://doi.org/10.1016/j.ejpb.2023.01.005.
Foglietta F, Pinnelli V, Giuntini F, Barbero N, Panzanelli P, Durando G, et al. Sonodynamic therapy induces selective killing of most cancers cells in an in vitro co-culture mannequin. Cancers. 2021;13(15):3852. https://doi.org/10.3390/cancers13153852.
Baroni S, Argenziano M, La Cava F, Soster M, Garello F, Lembo D, et al. Laborious-shelled glycol chitosan nanoparticles for twin MRI/US detection of drug supply/launch: a proof-of-concept research. Nanomaterials. 2023;13(15):2227. https://doi.org/10.3390/nano13152227.
Zhou Y, Gu N, Yang F. In situ microbubble-assisted, ultrasound-controlled launch of superparamagnetic iron oxide nanoparticles from gastro-retentive tablets. Int J Pharm. 2020;586:119615. https://doi.org/10.1016/j.ijpharm.2020.119615.
Rizzitelli S, Giustetto P, Faletto D, Delli Castelli D, Aime S, Terreno E. The discharge of doxorubicin from liposomes monitored by MRI and triggered by a mixture of US stimuli led to a whole tumor regression in a breast most cancers mouse mannequin. J Managed Launch: Official J Managed Launch Soc. 2016;230:57–63. https://doi.org/10.1016/j.jconrel.2016.03.040.
Brazzale C, Canaparo R, Racca L, Foglietta F, Durando G, Fantozzi R, Caliceti P, Salmaso S, Serpe L. Enhanced selective sonosensitizing efficacy of ultrasound-based anticancer therapy by focused gold nanoparticles. Nanomed (London England). 2016;11(23):3053–70. https://doi.org/10.2217/nnm-2016-0293.
Gorgizadeh M, Azarpira N, Lotfi M, Daneshvar F, Salehi F, Sattarahmady N. Sonodynamic most cancers remedy by a nickel ferrite/carbon nanocomposite on melanoma tumor: in vitro and in vivo research. Photodiagn Photodyn Ther. 2019;27:27–33. https://doi.org/10.1016/j.pdpdt.2019.05.023.
Perota G, Faghani-Eskandarkolaei P, Zahraie N, Zare MH, Sattarahmady N. A research of sonodynamic remedy of melanoma C540 cells in vitro by titania/gold nanoparticles. J Biomedical Phys Eng. 2024;14(1):43–54. https://doi.org/10.31661/jbpe.v0i0.2310-1674.
Shanei A, Akbari-Zadeh H. Investigating the sonodynamic-radiosensitivity impact of gold nanoparticles on HeLa cervical most cancers cells. J Korean Med Sci. 2019;34(37):e243. https://doi.org/10.3346/jkms.2019.34.e243.
Schroeder A, Kost J, Barenholz Y. Ultrasound, liposomes, and drug supply: rules for utilizing ultrasound to regulate the discharge of medicine from liposomes. Chem Phys Lipids. 2009;162(1–2):1–16. https://doi.org/10.1016/j.chemphyslip.2009.08.003.
Jamburidze A, Huerre A, Baresch D, Poulichet V, De Corato M, Garbin V. Nanoparticle-coated microbubbles for mixed ultrasound imaging and drug supply. Langmuir. 2019;35(31):10087–96. https://doi.org/10.1021/acs.langmuir.8b04008.
Batchelor DVB, Abou-Saleh RH, Coletta PL, McLaughlan JR, Peyman SA, Evans SD. Nested nanobubbles for ultrasound-triggered drug launch. ACS Appl Mater Interfaces. 2020;12(26):29085–93. https://doi.org/10.1021/acsami.0c07022.
Park JH, Lee BC, Search engine marketing YC, Kim JH, Kim DJ, Lee HJ, Moon H, Lee S. Drug supply by sonosensitive liposome and microbubble with acoustic-lens connected ultrasound: an in vivo feasibility research in a murine melanoma mannequin. Sci Rep. 2023;13(1):15798. https://doi.org/10.1038/s41598-023-42786-8.
Wooden AKW, Sehgal CM. A overview of low-intensity ultrasound for most cancers remedy. Ultrasound Med Biol. 2015;41(4):905–28. https://doi.org/10.1016/j.ultrasmedbio.2014.11.019.
Jiang X, Savchenko O, Li Y, Qi S, Yang T, Zhang W, et al. A overview of low-intensity pulsed ultrasound for therapeutic functions. IEEE Trans Biomed Eng. 2019;66(10):2704–18. https://doi.org/10.1109/TBME.2018.2889669.
Engelen Y, Krysko DV, Effimova I, Breckpot Okay, Versluis M, De Smedt S, et al. Optimizing high-intensity centered ultrasound-induced immunogenic cell-death utilizing passive cavitation mapping as a monitoring instrument. J Managed Launch. 2024;375:389–403. https://doi.org/10.1016/j.jconrel.2024.09.016.
Foglietta F, Macrì M, Panzanelli P, Francovich A, Durando G, Garello F, et al. Ultrasound boosts doxorubicin efficacy towards delicate and resistant ovarian most cancers cells. Eur J Pharm Biopharm. 2023;183:119–31. https://doi.org/10.1016/j.ejpb.2023.01.005.
Cohen G, Chandran P, Lorsung RM, Tomlinson LE, Sundby M, Burks SR, et al. The affect of centered ultrasound in two tumor fashions: temporal alterations within the pure historical past on tumor microenvironment and immune cell response. Cancers. 2020;12(2):350. https://doi.org/10.3390/cancers12020350.
Bromma Okay, Rieck Okay, Kulkarni J, O’Sullivan C, Sung W, Cullis P, et al. Use of a lipid nanoparticle system as a computer virus in supply of gold nanoparticles to human breast most cancers cells for improved outcomes in radiation remedy. Most cancers Nanotechnol. 2019;10(1):1. https://doi.org/10.1186/s12645-019-0046-z.
Baskar R, Lee KA, Yeo R, Yeoh Okay-W. Most cancers and radiation remedy: present advances and future instructions. Int J Med Sci. 2012;9(3):193. https://doi.org/10.7150/ijms.3635.
Pawlicki T, Scalliet P, Huq MS. Hendee’s Radiation Remedy Physics. Wiley; 2017.
Gibbons JP, Khan FM. Khan’s the Physics of Radiation Remedy. Wolters Kluwer; 2020.
Misra R, Sarkar Okay, Lee J, Pizzuti VJ, Lee DS, Currie MP, et al. Radioluminescent nanoparticles for radiation-controlled launch of medicine. J Managed Launch: Official J Managed Launch Soc. 2019;303:237–52. https://doi.org/10.1016/j.jconrel.2019.04.033.
Sarkar Okay, Torregrossa-Allen SE, Elzey BD, Narayanan S, Langer MP, Durm GA, et al. Impact of Paclitaxel stereochemistry on X-ray-triggered launch of Paclitaxel from CaWO4/Paclitaxel-coloaded PEG-PLA nanoparticles. Mol Pharm. 2022;19(8):2776–94. https://doi.org/10.1021/acs.molpharmaceut.2c00148.
Deng H, Lin L, Wang S, Yu G, Zhou Z, Liu Y, et al. X-ray-controlled bilayer permeability of bionic nanocapsules stabilized by nucleobase pairing interactions for pulsatile drug supply. Adv Mater. 2019;31(37):e1903443. https://doi.org/10.1002/adma.201903443.
Zhang L, Zhang S, Xu J, Li Y, He J, Yang Y, Huynh T, Ni P, Duan G, Yang Z, Zhou R. Low-Dose X-ray-Responsive diselenide nanoparticles for efficient supply of anticancer brokers. ACS Appl Mater Interfaces. 2020;12(39):43398–407. https://doi.org/10.1021/acsami.0c11627.
Deng W, Chen W, Clement S, Guller A, Zhao Z, Engel A, Goldys EM. Managed gene and drug launch from a liposomal supply platform triggered by X-ray radiation. Nat Commun. 2018;9(1):2713. https://doi.org/10.1038/s41467-018-05118-3.
Guo M, Solar Y, Zhang X-D. Enhanced radiation remedy of gold nanoparticles in liver most cancers. Appl Sci. 2017. https://doi.org/10.3390/app7030232.
Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a brand new X-ray distinction agent. Br J Radiol. 2006;79(939):248–53. https://doi.org/10.1259/bjr/13169882.
Schuemann J, Bagley AF, Berbeco R, Bromma Okay, Butterworth KT, Byrne HL, et al. Roadmap for metallic nanoparticles in radiation remedy: present standing, translational challenges, and future instructions. Phys Med Biol. 2020;65(21):21RM02. https://doi.org/10.1088/1361-6560/ab9159.
Zhigaltsev IV, Tam YYC, Kulkarni JA, Cullis PR. Synthesis and characterization of hybrid lipid nanoparticles containing gold nanoparticles and a weak base drug. Langmuir. 2022;38(25):7858–66. https://doi.org/10.1021/acs.langmuir.2c01221.
Uzel A, Agiotis L, Baron A, Zhigaltsev IV, Cullis PR, Kafshgari H, M., Meunier M. Single pulse nanosecond Laser-Stimulated focused supply of Anti-Most cancers medicine from hybrid lipid nanoparticles containing 5 Nm gold nanoparticles. Small. 2023;19(52):2305591. https://doi.org/10.1002/smll.202305591.
Li J, Solar Q, Lu C, Xiao H, Guo Z, Duan D, Zhang Z, Liu T, Liu Z. Boron encapsulated in a liposome can be utilized for combinational neutron seize remedy. Nat Commun. 2022;13(1):2143. https://doi.org/10.1038/s41467-022-29780-w.
Zhu M, Yang M, Zhang J, Yin Y, Fan X, Zhang Y, Qin S, Zhang H, Yu F. Immunogenic cell demise induction by ionizing radiation. Entrance Immunol. 2021;12:705361. https://doi.org/10.3389/fimmu.2021.705361.
Oyoshi, H., Du, J., Sakai, S. A., Yamashita, R., Okumura, M., Motegi, A., Hojo, H.,Nakamura, M., Hirata, H., Sunakawa, H., Kotani, D., Yano, T., Kojima, T., Nakamura,Y., Kojima, M., Suzuki, A., Zenkoh, J., Tsuchihara, Okay., Akimoto, T., … Kageyama, S.-I.(n.d.). Complete single-cell evaluation demonstrates radiotherapy-induced infiltration of macrophages expressing immunosuppressive genes into tumor in esophageal squamous cell carcinoma. Science Advances, 9(50), eadh9069. https://doi.org/10.1126/sciadv.adh9069.
Guo S, Yao Y, Tang Y, Xin Z, Wu D, Ni C, et al. Radiation-induced tumor immune microenvironments and potential targets for mixture remedy. Sign Transduct Goal Ther. 2023;8(1):205. https://doi.org/10.1038/s41392-023-01462-z.
Tips for Limiting Publicity to Electromagnetic Fields. (100 kHz to 300 GHz). Well being Phys. 2020;118(5):483–524. https://doi.org/10.1097/HP.0000000000001210.
Liu JF, Jang B, Issadore D, Tsourkas A. Use of magnetic fields and nanoparticles to set off drug launch and enhance tumor concentrating on. WIREs Nanomed Nanobiotechnol. 2019;11(6):e1571. https://doi.org/10.1002/wnan.1571.
Podaru GV, Chikan V, Prakash P. Magnetic area induced ultrasound from colloidal superparamagnetic nanoparticles. J Phys Chem C. 2016;120(4):2386–91. https://doi.org/10.1021/acs.jpcc.5b08535.
Podaru G, Moore J, Dani RK, Prakash P, Chikan V. Nested Helmholtz coil design for producing homogeneous transient rotating magnetic fields. Rev Sci Instrum. 2015;86(3):034701. https://doi.org/10.1063/1.4908173.
Podaru G, Ogden S, Baxter A, Shrestha T, Ren S, Thapa P, Dani RK, Wang H, Basel MT, Prakash P, Bossmann SH, Chikan V. Pulsed magnetic area induced quick drug launch from Magneto liposomes by way of ultrasound era. J Phys Chem B. 2014;118(40):11715–22. https://doi.org/10.1021/jp5022278.
Fuller EG, Solar H, Dhavalikar RD, Unni M, Scheutz GM, Sumerlin BS, Rinaldi C. Externally triggered warmth and drug launch from magnetically managed nanoparticles. ACS Appl Polym Mater. 2019;1(2):211–20. https://doi.org/10.1021/acsapm.8b00100.
Oliveira RR, Carrião MS, Pacheco MT, Branquinho LC, de Souza ALR, Bakuzis AF, et al. Triggered launch of Paclitaxel from magnetic strong lipid nanoparticles by magnetic hyperthermia. Supplies Science and Engineering: C. 2018;92:547–53. https://doi.org/10.1016/j.msec.2018.07.011.
Montis C, Castroflorio B, Mendozza M, Salvatore A, Berti D, Baglioni P. Magnetocubosomes for the supply and managed launch of therapeutics. J Colloid Interface Sci. 2015;449:317–26. https://doi.org/10.1016/j.jcis.2014.11.056.
Amstad E, Kohlbrecher J, Müller E, Schweizer T, Textor M, Reimhult E. Triggered launch from liposomes by way of magnetic actuation of iron oxide nanoparticle containing membranes. Nano Lett. 2011;11(4):1664–70. https://doi.org/10.1021/nl2001499.
Salvatore A, Montis C, Berti D, Baglioni P. Multifunctional magnetoliposomes for sequential managed launch. ACS Nano. 2016;10(8):7749–60. https://doi.org/10.1021/acsnano.6b03194.
Golovin YI, Zhigachev AO, Klyachko NL, Kabanov AV. Localizing the nanodeformation affect of magnetic nanoparticles on macromolecular objects by bodily and biochemical means. Bull Russian Acad Sciences: Phys. 2018;82(9):1073–8. https://doi.org/10.3103/S1062873818090095.
Tomitaka A, Takemura Y, Huang Z, Roy U, Nair M. Magnetoliposomes in controlled-release drug supply techniques. Crit Rev Biomed Eng. 2019;47(6):495. https://doi.org/10.1615/CritRevBiomedEng.2020033002.
Liu JF, Neel N, Dang P, Lamb M, McKenna J, Rodgers L, Litt B, Cheng Z, Tsourkas A, Issadore D. Radiofrequency-triggered drug launch from nanoliposomes with millimeter-scale decision utilizing a superimposed static gating area. Small. 2018;14(44):e1802563. https://doi.org/10.1002/smll.201802563.
Peiris PM, Bauer L, Toy R, Tran E, Pansky J, Doolittle E, et al. Enhanced supply of chemotherapy to tumors utilizing a multi-component nanochain with radiofrequency-tunable drug launch. ACS Nano. 2012;6(5):4157–68. https://doi.org/10.1021/nn300652p.
Peiris PM, Tam M, Vicente P, Abramowski A, Toy R, Bauer L, Mayer A, Pansky J, Doolittle E, Tucci S, Schmidt E, Shoup C, Rao S, Murray Okay, Gopalakrishnan R, Keri RA, Basilion JP, Griswold MA, Karathanasis E. On-command drug launch from nanochains inhibits progress of breast tumors. Pharm Res. 2014;31(6):1460–8. https://doi.org/10.1007/s11095-013-1102-8.
Peiris PM, Toy R, Abramowski A, Vicente P, Tucci S, Bauer L, et al. Remedy of most cancers micrometastasis utilizing a multicomponent chain-like nanoparticle. J Management Launch. 2014. https://doi.org/10.1016/j.jconrel.2013.10.031.
Peiris PM, Abramowski A, Mcginnity J, Doolittle E, Toy R, Gopalakrishnan R, et al. Remedy of invasive mind tumors utilizing a chain-like nanoparticle. Most cancers Res. 2015;75(7):1356–65. https://doi.org/10.1158/0008-5472.CAN-14-1540.
Alabi OA, Silva AH, Rode MP, Pizzol CD, de Campos AM, Filippin-Monteiro FB, et al. In vitro cytotoxicity of co-exposure to superparamagnetic iron oxide and strong lipid nanoparticles. Toxicol Ind Well being. 2021;37(2):77–89. https://doi.org/10.1177/0748233720977383.
Li F, Qin Y, Lee J, Liao H, Wang N, Davis TP, et al. Stimuli-responsive nano-assemblies for remotely managed drug supply. J Managed Launch: Official J Managed Launch Soc. 2020;322:566–92. https://doi.org/10.1016/j.jconrel.2020.03.051.
Chander N, Morstein J, Bolten JS, Shemet A, Cullis PR, Trauner D, Witzigmann D. Optimized Photoactivatable Lipid Nanoparticles Allow Pink Gentle Triggered Drug Launch. Small. 2021;17(21):2008198. https://doi.org/10.1002/smll.202008198
Boutopoulos C, Bergeron E, Meunier M. Cell perforation mediated by plasmonic bubbles generated by a single close to infrared femtosecond laser pulse. J Biophotonics. 2016;9(1–2):26–31. https://doi.org/10.1002/jbio.201500135.
Xiong R, Samal SK, Demeester J, Skirtach AG, De Smedt SC, Braeckmans Okay. Laser-assisted photoporation: fundamentals, technological advances and functions. Adv Physics: X. 2016;1(4):596–620. https://doi.org/10.1080/23746149.2016.1228476.
Boulais E, Lachaine R, Hatef A, Meunier M. Plasmonics for pulsed-laser cell nanosurgery: fundamentals and functions. J Photochem Photobiol C. 2013;17:26–49. https://doi.org/10.1016/j.jphotochemrev.2013.06.001.
Darviot C, Hardy P, Meunier M. Laser-induced plasmon-mediated therapy of retinoblastoma in viscous vitreous phantom. J Biophotonics. 2019;12(11):e201900193. https://doi.org/10.1002/jbio.201900193.
Carter KA, Shao S, Hoopes MI, Luo D, Ahsan B, Grigoryants VM, Track W, Huang H, Zhang G, Pandey RK, Geng J, Pfeifer BA, Scholes CP, Ortega J, Karttunen M, Lovell JF. Porphyrin-phospholipid liposomes permeabilized by near-infrared mild. Nat Commun. 2014;5:3546. https://doi.org/10.1038/ncomms4546.
Dariva CG, Coelho JFJ, Serra AC. Close to infrared light-triggered nanoparticles utilizing singlet oxygen photocleavage for drug supply techniques. J Managed Launch. 2019;294:337–54. https://doi.org/10.1016/j.jconrel.2018.12.042.
Dai Y, Su J, Wu Okay, Ma W, Wang B, Li M, et al. Multifunctional thermosensitive liposomes primarily based on pure phase-change materials: near-infrared light-triggered drug launch and multimodal imaging-guided most cancers mixture remedy. ACS Appl Mater Interfaces. 2019;11(11):10540–53. https://doi.org/10.1021/acsami.8b22748.
Fang F, Zhang X, Tang J, Wang Y, Xu J, Solar Y. EGFR-targeted hybrid lipid nanoparticles for chemo-photothermal remedy towards colorectal most cancers cells. Chem Phys Lipids. 2023;251:105280. https://doi.org/10.1016/j.chemphyslip.2023.105280.
Viitala L, Pajari S, Lajunen T, Kontturi L-S, Laaksonen T, Kuosmanen P, et al. Photothermally triggered lipid bilayer part transition and drug launch from gold nanorod and indocyanine inexperienced encapsulated liposomes. Langmuir. 2016;32(18):4554–63. https://doi.org/10.1021/acs.langmuir.6b00716.
Zhang Okay, Zhang Y, Meng X, Lu H, Chang H, Dong H, Zhang X. Gentle-triggered theranostic liposomes for tumor analysis and mixed photodynamic and hypoxia-activated prodrug remedy. Biomaterials. 2018;185:301–9. https://doi.org/10.1016/j.biomaterials.2018.09.033.
U.S. Meals and Drug Administration. (2018). SPY AGENT Inexperienced (Indocyanine Inexperienced): Multidisciplinary abstract overview (NDA #211580). Retrieved from https://www.fda.gov/information/medicine/printed/383_211580percent20indocyaninepercent20greenpercent20unireviewpercent20prea.pdf
Yao L, Bojic D, Liu M. Purposes and security of gold nanoparticles as therapeutic gadgets in medical trials. J Pharm Anal. 2023;13(9):960–7. https://doi.org/10.1016/j.jpha.2023.06.001.
Yegorov YE, Vishnyakova KS, Pan X, Egorov AE, Popov KV, Tevonyan LL, Chashchina GV, Kaluzhny DN. Mechanisms of phototoxic results of cationic porphyrins on human cells in vitro. Molecules. 2023;28(3):1090. https://doi.org/10.3390/molecules28031090.
de Oliveira GV, Soares MV, Cordeiro LM, da Silva AF, Venturini L, Ilha L, Baptista FBO, da Silveira TL, Soares FAA, Iglesias BA. Toxicological evaluation of photoactivated tetra-cationic porphyrin molecules below white mild publicity in a caenorhabditis elegans mannequin. Toxicology. 2024;504:153793. https://doi.org/10.1016/j.tox.2024.153793.
Londoño-Berrío M, Pérez-Buitrago S, Ortiz-Trujillo IC, Hoyos-Palacio LM, Orozco LY, López L, et al. Cytotoxicity and genotoxicity of Azobenzene-based polymeric nanocarriers for phototriggered drug launch and biomedical functions. Polymers. 2022;14(15):3119. https://doi.org/10.3390/polym14153119.
Mulatihan D, Guo T, Zhao Y. Azobenzene photoswitch for isomerization-dependent most cancers remedy by way of Azo-Combretastatin A4 and phototrexate. Photochem Photobiol. 2020;96(6):1163–8. https://doi.org/10.1111/php.13292.
Ge R, Wang Z, Cheng L. Tumor microenvironment heterogeneity an vital mediator of prostate most cancers development and therapeutic resistance. NPJ Summary Oncol. 2022;6(1):31. https://doi.org/10.1038/s41698-022-00272-w.
Paliwal R, Babu RJ, Palakurthi S. Nanomedicine scale-up applied sciences: feasibilities and challenges. AAPS PharmSciTech. 2014;15(6):1527–34. https://doi.org/10.1208/s12249-014-0177-9.
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Most cancers nanomedicine: progress, challenges and alternatives. Nat Rev Most cancers. 2017;17(1):20–37. https://doi.org/10.1038/nrc.2016.108.
Hermans R, Meijerink M, Bogaert WV, den, Rijnders A, Weltens C, Lambin P. Tumor perfusion fee decided noninvasively by dynamic computed tomography predicts final result in head-and-neck most cancers after radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57(5):1351–6. https://doi.org/10.1016/S0360-3016(03)00764-8.
Stylianopoulos T, Munn LL, Jain RK. Reengineering the bodily microenvironment of tumors to enhance drug supply and efficacy: from math modeling to bench to bedside. Developments Most cancers. 2018;4(4):292. https://doi.org/10.1016/j.trecan.2018.02.005.
Manzoor AA, Lindner LH, Landon CD, Park J-Y, Simnick AJ, Dreher MR, Das S, Hanna G, Park W, Chilkoti A, Koning GA, ten Hagen TL, Needham D, Dewhirst MW. Overcoming limitations in nanoparticle drug supply: triggered, intravascular launch to enhance drug penetration into tumors. Most cancers Res. 2012;72(21):5566. https://doi.org/10.1158/0008-5472.CAN-12-1683.
ten Hagen TLM, Dreher MR, Zalba S, Seynhaeve ALB, Amin M, Li L, et al. Drug transport kinetics of intravascular triggered drug supply techniques. Commun Biol. 2021;4(1):1–17. https://doi.org/10.1038/s42003-021-02428-z.
Johnson-Arbor Okay, Dubey R. Doxorubicin. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Accessible from: https://www.ncbi.nlm.nih.gov/books/NBK459232/
DailyMed—DOXORUBICIN HYDROCHLORIDE-. doxorubicin hydrochloride injection, answer. [Updated 2024 Oct 14] Retrieved Could, 2025, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0349f98-42fa-4003-b6d8-a1db1401b0ef
Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet. 2003;42(5):419–36. https://doi.org/10.2165/00003088-200342050-00002.
DailyMed—DOXIL- doxorubicin. hydrochloride injection, suspension, liposomal. [Updated 2022 May 31] Retrieved Could, 2025, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c153e9e-4cf2-4ac7-9cf9-16f9b48d7dce
Sritharan S, Sivalingam N. A complete overview on time-tested anticancer drug doxorubicin. Life Sci. 2021;278:119527. https://doi.org/10.1016/j.lfs.2021.119527.
Fidler IJ, Kripke ML. The problem of concentrating on metastasis. Most cancers Metastasis Rev. 2015;34(4):635–41. https://doi.org/10.1007/s10555-015-9586-9.
Lu TSAY-J, Chen J-P. Optimization of the preparation of magnetic liposomes for the mixed use of magnetic hyperthermia and photothermia in twin magneto-photothermal most cancers remedy. Int J Mol Sci. 2020;21(15):5187. https://doi.org/10.3390/ijms21155187.
Shahsavari S, Rad MB, Hajiaghajani A, Rostami M, Hakimian F, Jafarzadeh S, et al. Magnetoresponsive liposomes functions in nanomedicine: a complete overview. Biomed Pharmacother. 2024;181:117665. https://doi.org/10.1016/j.biopha.2024.117665.
Huber CM, Pavan TZ, Ullmann I, Heim C, Rupitsch SJ, Vossiek M, et al. A overview on ultrasound-based strategies to picture the distribution of magnetic nanoparticles in biomedical functions. Ultrasound Med Biol. 2025;51(2):210–34. https://doi.org/10.1016/j.ultrasmedbio.2024.10.007.
Dwivedi P, Kiran S, Han S, Dwivedi M, Khatik R, Fan R, et al. Magnetic concentrating on and ultrasound activation of liposome–microbubble conjugate for enhanced supply of anticancer therapies. ACS Appl Mater Interfaces. 2020. https://doi.org/10.1021/acsami.0c05308.
Senjab M, AlSawaftah R, Abuwatfa NH, W., Husseini A, G. Advances in liposomal nanotechnology: from idea to clinics. RSC Pharm. 2024;1(5):928–48. https://doi.org/10.1039/D4PM00176A.